1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

FDA objects to AstraZeneca sales rep touting off-label Seroquel

 
• By Nancy Faigen

In a letter toAstraZeneca, the USFDA's division of drug marketing, advertising and communication stated that it has become aware of an incident whereby a sales rep from the company suggested an unapproved use for Seroquel (quetiapine fumarate).

In a letter toAstraZeneca, the USFDA's division of drug marketing, advertising and communication stated that it has become aware of an incident whereby a sales rep from the company suggested an unapproved use for Seroquel (quetiapine fumarate).

In the letter, the agency claimed that the sales rep told a doctor in January 2008 that Seroquel was approved for treating major depressive disorder. The doctor then requested information...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapeutic Category

ASCO: J&J Banks On T-Cell Engager’s Safety In Prostate Cancer

 
• By Andrew McConaghie

The company highlighted the KLK2-targeting agent’s safety at ASCO but it may have to rely on combinations to make pasritamig competitive.

ASCO: Regeneron Looks To Become Bigger Immuno-Oncology Player

 
• By Alaric DeArment

The drugmaker presented oral abstracts at the meeting for Libtayo in adjuvant cutaneous squamous-cell carcinoma and linvoseltamab in multiple myeloma.

ASCO: Lupin Presents Early Data On PRMT5 Inhibitor

 
• By Vibha Ravi

ASCO sees the debut of Lupin’s PRMT5 inhibitor candidate LRNP7457, currently in Phase I studies in India. While no drug with this mechanism of action has been approved anywhere so far, several candidates are in clinical trials.